Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials
Journal of the National Comprehensive Cancer Network · 2026-05 · 24 (5) · 163-171
DOI: 10.6004/jnccn.2025.7135 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-05. Verfasst von Bruno Almeida Costa und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Methylphenidate, Neoplasms, Fatigue, Central Nervous System Stimulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben.
Abstract (Originalsprache)
Background
Nonpharmacologic interventions are the mainstay of management for cancer-related fatigue (CRF), with few pharmacologic options available—notably methylphenidate (MPH) and dexmethylphenidate (d-MPH). Given mixed evidence from randomized controlled trials (RCTs) and newly published phase III data, we conducted an updated systematic review and meta-analysis to clarify the efficacy and safety of these psychostimulants in managing CRF.
Methods
PubMed, Embase, and CENTRAL were searched through January 2025 for placebo-controlled, double-blind RCTs evaluating MPH/d-MPH in adults with advanced cancer or receiving active cancer-directed therapy. Outcomes included between-group differences in fatigue score changes measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), self-rated 0–10 scales, or any validated scales, as well as treatment-emergent adverse events (TEAEs). Exploratory subanalyses examined FACIT-F score changes at 2 ± 1, 5 ± 1, and ≥8 weeks after treatment initiation. Pooled estimates were calculated using random-effects models.
Results
A total of 9 RCTs met inclusion criteria (n=823; with evaluable sample sizes varying per analysis). Compared with placebo, MPH/d-MPH monotherapy (MPH-equivalent dose range: 5–100 mg/d) produced statistically significant improvements in fatigue scores, as measured by FACIT-F (mean difference [MD], 2.43; 95% CI, 0.90 to 3.96), self-rated 0–10 scales (MD, −1.52; 95% CI, −2.90 to −0.14), and any validated scale (standardized MD, 0.38; 95% CI, 0.17 to 0.60). FACIT-F improvements followed a temporal gradient, exceeding the 3-point threshold for clinical meaningfulness by 5 ± 1 weeks (MD, 3.56; 95% CI, 1.57 to 5.55) and rising further by ≥8 weeks (MD, 3.89; 95% CI, 1.76 to 6.01). No statistically significant differences in the odds of key TEAEs were observed.
Conclusions
MPH-type psychostimulants produce a modest but consistent reduction in CRF, with therapeutic benefits becoming clinically meaningful after 5 weeks and a favorable safety profile in the studied population, thereby meriting consideration for carefully selected individuals living with cancer when nonpharmacologic strategies are insufficient or still taking effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- 2Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
- 3Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
- 4Department of Behavioral Health, Saint Elizabeths Hospital, Washington, DC.
- 5Department of Psychiatry, Hospital Juliano Moreira, Salvador, Bahia, Brazil.
- 6Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Zitieren
APA
Costa, B. A., Sheppard, R., Coelho, H. G. B., Crowley, F., Oliveira, D., Costa, V. A., Chen, J., Afezolli, D., DeCastro, G. A., Apoeso, O., Popp, B., Curseen, K. A., & Quest, T. E. (2026). Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network, 24(5), 163-171. https://doi.org/10.6004/jnccn.2025.7135
Vancouver
Costa BA, Sheppard R, Coelho HGB, Crowley F, Oliveira D, Costa VA, et al. Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network. 2026;24(5):163-171. doi:10.6004/jnccn.2025.7135
BibTeX
@article{Costa2026,
author = {Costa, Bruno Almeida and Sheppard, Richard and Coelho, Henrique G B and Crowley, Fionnuala and Oliveira, Debora and Costa, Victor Almeida and Chen, Joanna and Afezolli, Debora and DeCastro, Gene A and Apoeso, Olusegun and Popp, Beth and Curseen, Kimberly A and Quest, Tammie E},
title = {Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {5},
pages = {163--171},
doi = {10.6004/jnccn.2025.7135}
}
EUVIMED